Eupraxia shares move to Nasdaq Global Select

Eupraxia Pharmaceuticals upgrades to Nasdaq’s top market tier and schedules multiple New York investor conference appearances in September 2026.

Rhea-AI Filing Summary

Eupraxia Pharmaceuticals Inc. (EPRX) announced that its common shares have commenced trading on the Nasdaq Global Select Market, having transferred from the Nasdaq Capital Market, while continuing to trade on the Toronto Stock Exchange under the same ticker. No action is required by shareholders in connection with the transfer. Management stated that meeting Nasdaq’s highest market tier requirements reflects the company’s progress as it advances its clinical programs.

The company also plans to engage investors through several conferences in New York in September 2026, including events hosted by Cantor, H.C. Wainwright and Morgan Stanley, featuring fireside chats, company presentations and one-on-one meetings.

Positive

• Common shares began trading on the Nasdaq Global Select Market, Nasdaq’s highest market tier, which is reserved for companies meeting more stringent financial, liquidity and governance standards.

Negative

• None.

Key Figures

Market tier: Nasdaq Global Select Market Cantor fireside chat date and time: September 11, 2026 at 9:45am H.C. Wainwright presentation date and time: September 14, 2026 at 2:00pm +2 more

5 metrics

Market tier Nasdaq Global Select Market New listing tier for Eupraxia common shares, previously on Nasdaq Capital Market

Cantor fireside chat date and time September 11, 2026 at 9:45am Scheduled Cantor Global Healthcare Conference fireside chat in New York

H.C. Wainwright presentation date and time September 14, 2026 at 2:00pm Scheduled company presentation at H.C. Wainwright 28th Annual Global Investment Conference

Morgan Stanley conference meeting dates September 15–16, 2026 Scheduled one-on-one meetings at Morgan Stanley 24th Annual Global Healthcare Conference

Clinical stage of EP-104GI Phase 1b/2 trial RESOLVE trial for treatment of eosinophilic esophagitis (EoE)

Key Terms

Nasdaq Global Select Market, Diffusphere™, Phase 1b/2 trial, eosinophilic esophagitis (EoE), +1 more

5 terms

Nasdaq Global Select Market market

"common shares have commenced trading on the Nasdaq Global Select Market."

A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.

Diffusphere™ technical

"leveraging its proprietary Diffusphere™ technology designed to optimize local,"

Phase 1b/2 trial medical

"EP-104GI is currently in a Phase 1b/2 trial, the RESOLVE trial,"

A phase 1b/2 trial is a combined early-stage clinical study that links dose-finding and safety evaluation (phase 1b) with preliminary testing of effectiveness and additional safety data (phase 2). It typically starts by identifying a safe or optimal dose and may expand one or more patient groups at that dose to measure signals of clinical activity using predefined endpoints; designs often use small to moderate sample sizes and can be adaptive (for example, changing dose cohorts or enrollment based on interim results). The trial’s purpose is to confirm an appropriate dose and gather initial evidence of benefit and tolerability that would justify larger, definitive trials.

eosinophilic esophagitis (EoE) medical

"the RESOLVE trial, for the treatment of EoE."

A chronic allergic condition in which white blood cells called eosinophils build up in the esophagus, causing inflammation that can make swallowing difficult, trigger chest pain, and sometimes lead to food getting stuck. Think of the esophagus like a garden hose that becomes narrowed and irritated by sticky residue; treatment often requires ongoing medication, dietary changes, or procedures. Investors watch this condition because it creates steady demand for drugs, medical devices, and diagnostic services, and can drive regulatory reviews and reimbursement decisions.

extended-release products medical

"development of locally delivered, extended-release products that have the potential"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What Nasdaq change did EPRX announce in this Form 6-K?

Eupraxia Pharmaceuticals’ common shares have commenced trading on the Nasdaq Global Select Market, transferring from the Nasdaq Capital Market, and will continue under the ticker symbol EPRX.

Does the Nasdaq Global Select Market transfer affect EPRX’s TSX listing?

No. Eupraxia stated that its listing on the Toronto Stock Exchange remains unchanged, and its common shares continue to trade there under the ticker EPRX.

Do EPRX shareholders need to take any action after the Nasdaq transfer?

No. Eupraxia specifically noted that no action is required by shareholders in connection with the transfer of its listing to the Nasdaq Global Select Market.

Which investor conferences will EPRX participate in September 2026?

Eupraxia plans to participate in the Cantor Global Healthcare Conference, the H.C. Wainwright 28th Annual Global Investment Conference, and the Morgan Stanley 24th Annual Global Healthcare Conference in New York.

When is Eupraxia’s Cantor Global Healthcare Conference fireside chat scheduled?

The fireside chat at the Cantor Global Healthcare Conference is scheduled for September 11, 2026 at 9:45am, with the company also holding one-on-one investor meetings at the event in New York.

What stage is Eupraxia’s EP-104GI program mentioned in the filing?

Eupraxia reported that EP-104GI is in a Phase 1b/2 trial, called the RESOLVE trial, for the treatment of eosinophilic esophagitis (EoE), using local injection into the esophageal wall.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 08:05 AM EDT Accepted by SEC EDGAR 09/08/2026 - 08:05 AM EDT Learn about SEC filing dates

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2026

Commission File Number: 001-41923

EUPRAXIA PHARMACEUTICALS INC.
(Exact name of Registrant as specified in its charter)

N/A
(Translation of Registrant’s name)

2198 Yukon Street
Vancouver, British Columbia, Canada V5Y 3P1
Telephone: (250) 590-3968 
(Address and telephone number of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [   ]      Form 40-F [ X ]

DOCUMENTS INCLUDED AS PART OF THIS REPORT

Exhibit
99.1		Press Release dated September 8, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	EUPRAXIA PHARMACEUTICALS INC.
Date: September 8, 2026	By:	/s/ Alex Rothwell
		Name: Alex Rothwell
		Title: Chief Financial Officer

EXHIBIT 99.1

Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (Nasdaq: EPRX) (TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced today that its common shares have commenced trading on the Nasdaq Global Select Market. The Company also announced that members of its management team will participate in upcoming investor conferences.

The Company’s common shares were previously listed on the Nasdaq Capital Market and will continue to trade under the ticker symbol “EPRX.” Eupraxia’s listing on the Toronto Stock Exchange remains unchanged. No action is required by shareholders in connection with the transfer.

The Nasdaq Global Select Market is Nasdaq’s highest market tier and is reserved for companies that satisfy its most stringent initial financial and liquidity requirements, in addition to applicable corporate governance standards.

“Eupraxia’s graduation to the Nasdaq Global Select Market reflects the progress and growth of the Company,” said Alex Rothwell, Chief Financial Officer of Eupraxia. “We are pleased to have met the requirements for Nasdaq’s highest market tier as we continue advancing our clinical programs and working to create long-term value for patients and shareholders.”

In addition, Company management will present and participate in the following upcoming investor conferences:

Cantor Global Healthcare Conference
Format: Fireside Chat & 1x1 Meetings
Fireside Chat Date & Time: September 11, 2026 at 9:45am ET
Webcast Link
Location: New York, NY

H.C. Wainwright 28^th Annual Global Investment Conference
Format: Company Presentation & 1x1 Meetings
Company Presentation Date & Time: September 14, 2026 at 2:00pm ET
Webcast Link
Location: New York, NY

Morgan Stanley 24^th Annual Global Healthcare Conference
Format: 1x1 Meetings
Date: September 15 & 16, 2026
Location: New York, NY

About Eupraxia Pharmaceuticals Inc.

Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Diffusphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The technology is designed to support extended duration of effect and delivery of drugs in a hyper-localized fashion, targeting only the tissues that physicians are wanting to treat. We believe the potential for fewer adverse events may be achieved through the precision targeting and the stable and flat delivery of the active ingredient when using the Diffusphere™ technology, versus the peaks and troughs seen with more traditional drug delivery methods. The precision of Eupraxia's Diffusphere™ technology platform has the potential to augment and transform existing FDA-approved drugs to improve their safety, tolerability, efficacy and duration of effect. The potential uses in therapeutic areas may go beyond pain and inflammatory gastrointestinal disease, where Eupraxia currently is developing advanced treatments, to also be applicable in oncology, infectious disease and other critical disease areas.  

Eupraxia's EP-104GI is currently in a Phase 1b/2 trial, the RESOLVE trial, for the treatment of EoE. EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug.  This is a unique treatment approach for EoE. In addition, Eupraxia is developing a pipeline of later and earlier-stage long-acting formulations.  For further details about Eupraxia, please visit the Company's website at: www.eupraxiapharma.com. 
  

For investor and media inquiries, please contact:

James Meikle, Eupraxia Pharmaceuticals Inc.
236.330.7084
jmeikle@eupraxiapharma.com

or

Kevin Gardner, on behalf of:
Eupraxia Pharmaceuticals Inc.
617.283.2856
kgardner@lifesciadvisors.com

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE 5.5 KB